Munich, February, 29^th 2024 – Munich based Mecuris GmbH and Ottobock SE & Co. KGaA agreed on the transfer of technology for the creation of individualized O&P devices. The software developed for the Mecuris Solution Platform enables orthopaedic technicians to design and build customized 3D-printed prosthetic- and orthotic-products.

Diepenbeek, Belgium, February 21st, 2024 – Rejuvenate Biomed NV ("Rejuvenate Biomed"), a pioneering clinical-stage platform and pipeline company committed to enhancing lifelong health through innovative therapeutics, today announces breakthrough functional outcome results from its Phase 1b trial of lead candidate RJx-01 for the treatment of sarcopenia.

SAN FRANCISCO, February 16, 2024 – Caresyntax, a pioneer in surgical intelligence and automation technologies, is excited to announce its recognition as one of the Fierce Healthcare's Fierce 15 of 2024, a prestigious acknowledgment of the most innovative healthcare companies across the United States.

Schlieren / Zurich, Switzerland, February 5, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies for viral infections and oncology, announced today that it has strengthened its senior team with the appointments of Kristie B. Clemmer and Dr. Maartje Verschuur as VP Clinical Operations and VP CMC and Supply Chain Management, respectively, effective today.

Munich, Germany, December 6, 2023 – CatalYm announced that maturing Phase 2a results from its ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 in Geneva, Switzerland.

Schlieren / Zurich, Switzerland – November 16, 2023 – Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).

Schlieren / Zurich, Switzerland – November 2, 2023 – Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series C financing led by Pureos Bioventures.

Diepenbeek, Belgium, October 4, 2023 – Rejuvenate Biomed NV ("Rejuvenate Biomed"), a clinical-stage company dedicated to advancing therapeutics to delay the onset of age-related diseases, today announced the successful completion of a 6-week clinical proof-of-mechanism study with lead candidate RJx-01. RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.

Munich, Germany, July 20, 2023 – CatalYm today announced the publication of preclinical data in Nature Communications under the title "Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment". The study reveals a central role of GDF-15 in the resistance of tumors to current immunotherapy.

July 3, 2023 – OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 M€, entirely subscribed by its current shareholders.